Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
about
Melanoma: oncogenic drivers and the immune systemAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeImmune checkpoint blockade: a common denominator approach to cancer therapyAntibody Therapies in Cancer.Rational combinations of immunotherapeutics that target discrete pathways.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.Inhibitory receptors as targets for cancer immunotherapyHumanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillanceBlocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewImmunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1αB7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma.B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Immunotherapy of melanoma: present options and future promises.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Immunotherapy for advanced melanoma: future directions.B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.Interplay between Immune Checkpoint Proteins and Cellular Metabolism.The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.B7-H3 in tumors: friend or foe for tumor immunity?Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.[Immunotherapy for HNSCC : Quo vadis?].
P2860
Q26775598-D55B9CDF-15C2-480C-8D0F-B7317612068AQ28079016-93866722-CB6F-48F8-9FCF-6B5563EDC953Q28083981-93BD299D-BEC4-493E-9690-D7765178088DQ31104000-02887AA5-22AB-44D9-B368-19046A3C0749Q33606144-923EEA7D-588E-4477-9D02-6956ACA1AA1FQ34548319-F83D1F1B-8D3E-485E-841E-EAFFEA1CDBC6Q34658452-F3C852D0-7D8B-4E42-8447-53ACB61C7540Q35043619-DDAF87AA-F91C-4845-A94A-C6EE737AAA8EQ35995373-6982821C-FC1B-4426-A3EC-61A555CBC20EQ36444198-B9986DA3-6565-408B-B761-7AC10E35590CQ36597354-3FB05691-88DA-4D46-B7A1-EF4AF4747115Q36806906-E1B57CCD-40A8-4414-9F1C-D043A0C02837Q36921665-93BD88DF-891C-421A-8D8C-B979A5E04D50Q37301864-C739605C-93FB-434C-BC2B-D8C2B5C40A62Q37324190-A5AC7D6F-1FB1-44F8-996C-52AED3DA7B07Q37738088-27E2DF71-910A-4276-8EA4-5E5CC47C6155Q38194135-1F32C8CC-EFC4-4FA9-97E5-CA1865E04CE0Q38318683-DCFB510F-65E7-46BF-8F34-A60AC0C4733BQ38595251-A622CAD9-0070-4B34-9BA1-34F407F09580Q38666253-F1221A9C-CEDE-48CB-BD76-A5FD56D5407FQ38670099-323486E1-19E3-4B1B-AFDD-DDBECD8F4E23Q38673585-0D33F56A-7B30-4E7E-9354-0C5ED302A858Q38684886-C6E943A4-8717-43BE-99DC-3D8811308B3CQ38708078-7494ADA9-53BA-479E-9D02-9F553CB67ED5Q38711163-F0806B53-D613-40B4-9723-80D3FBD02E81Q38768316-65BACFB9-7132-4085-9C79-0CD5F170EAD4Q38856131-BDB11DE4-B5EA-400A-AC1A-D499F0B874D8Q39155250-F14DDEB2-5484-4E98-9E53-D3B7E0D0F956Q39160982-DB90F658-C9E1-4FE4-A796-BFBB439C37E5Q39415827-D20B9367-9D2F-430F-81C3-AFCBBA89F80BQ39446788-4D2A78A8-EF33-490D-876C-7643096F6B36Q41809391-87C49C20-2387-415B-8242-C5DE88A5D65FQ42173120-22A62B34-7427-4C64-AE6B-AF21E07E661FQ42557137-A8AB32CC-CA06-41FC-B714-859D435CF04CQ42906644-CCE3D799-C827-4C3C-9E66-F6D9F77406AFQ47233613-5819312C-387C-4D38-9426-5A1C3CBBFFBAQ48131888-54525508-C828-408E-BF1F-42F7FBE913B2Q50983217-D9508C0E-16F2-4A25-B7D7-44EEFAAB5AF0Q51238255-D41FD621-742A-4EDE-9A3D-BBD6C36E536EQ51319375-5D54E607-60FB-4E29-A824-1AB32B8C639B
P2860
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Development of an Fc-enhanced ...... ith potent antitumor activity.
@en
Development of an Fc-enhanced ...... ith potent antitumor activity.
@nl
type
label
Development of an Fc-enhanced ...... ith potent antitumor activity.
@en
Development of an Fc-enhanced ...... ith potent antitumor activity.
@nl
prefLabel
Development of an Fc-enhanced ...... ith potent antitumor activity.
@en
Development of an Fc-enhanced ...... ith potent antitumor activity.
@nl
P2093
P1476
Development of an Fc-enhanced ...... ith potent antitumor activity.
@en
P2093
Ann N Easton
Claudia Fieger
Ezio Bonvini
Francine Z Chen
Jennie P Mather
Jill R Rillema
Jonathan C Li
Ling Huang
P304
P356
10.1158/1078-0432.CCR-12-0715
P407
P577
2012-05-21T00:00:00Z